Marc Garnier, MD, PhD

University Hospital, Clermont-Ferrand · Assistance Publique - Hôpitaux de Paris

Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.

Registry trials as an overall official

all conditions, ClinicalTrials.gov

NIH grants tied to them

NIH RePORTER

Trial papers in breast cancer

PubMed author-name match

Trials

Studies that name Marc Garnier, MD, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:58 UTC. Open this list on ClinicalTrials.gov

Ph3
NCT07898943 · Evaluation of the Effect of Antibiotic Prophylaxis During Lumpectomy for Breast Cancer: Prospective Randomised Double-blind Noninferiority Study of Placebo vs Cefazolin
University Hospital, Clermont-Ferrand · not yet recruiting · Breast Cancer, Breast Surgery, Surgical Site Infection (SSI) · principal investigator
N/A
NCT03147807 · BetaLACTA® Test for Early De-escalation of Empirical Carbapenems in Pulmonary, Urinary and Bloodstream Infections in ICU
Assistance Publique - Hôpitaux de Paris · completed · Pneumonia, Urinary Tract Infections, Bloodstream Infection · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 12:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.

Most cited trial papers

PubMed returned no clinical-trial papers for this author name in breast cancer.